Ampio Pharmaceuticals, Inc. Sample Contracts

INDEMNIFICATION AGREEMENT
Indemnification Agreement • March 29th, 2022 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ________, 2021 between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and __________ (“Indemnitee”).

AutoNDA by SimpleDocs
AMPIO PHARMACEUTICALS, INC. Common Stock ($0.0001 value per share) Sales Agreement
Sales Agreement • February 20th, 2020 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • June 6th, 2017 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 2, 2017, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

AT THE MARKET OFFERING AGREEMENT September 18, 2023
Market Offering Agreement • September 18th, 2023 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

Ampio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:

AMPIO PHARMACEUTICALS, INC. Common Stock (par value $0.0001) PLACEMENT AGENT AGREEMENT
Placement Agent Agreement • December 21st, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMPIO PHARMACEUTICALS, INC. EQUITY DISTRIBUTION AGREEMENT
Equity Distribution Agreement • April 15th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”), as of the date first written above, as follows:

Ampio Pharmaceuticals, Inc. 8,500,000 Shares Common Stock ($0.0001 par value) plus an option to purchase from the Company up to 1,275,000 additional Shares of Common Stock Underwriting Agreement
Ampio Pharmaceuticals, Inc. • February 28th, 2014 • Pharmaceutical preparations • New York

Ampio Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $.0001 par value (“Common Stock”), of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company collectively being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”).

EMPLOYMENT AGREEMENT
Employment Agreement • August 29th, 2017 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

This Employment Agreement (the "Agreement"), is effective as of August 16, 2017 (the “Effective Date”), and executed August 23, 2017 between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Thomas E. Chilcott, III (“Employee").

PLACEMENT AGENCY AGREEMENT June 17, 2019
Placement Agency Agreement • June 17th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

Introductory. This Placement Agency Agreement the (“Agreement”) sets forth the terms upon which ThinkEquity, a division of Fordham Financial Management, Inc., (“ThinkEquity” or the “Placement Agent”) shall be engaged by Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to act as the exclusive Placement Agent in connection with the offering (hereinafter referred to as the “Offering”) of securities of the Company, as more fully described below. Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to them in the Securities Purchase Agreement (defined below).

4,615,400 Shares of Common Stock AMPIO PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • July 13th, 2012 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
FORM OF SECURITIES PURCHASE AGREEMENT
Form of Securities Purchase Agreement • August 29th, 2016 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of , 2016, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • June 17th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of June 17, 2019, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

INDEMNIFICATION AGREEMENT
Indemnification Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate • Delaware

This Indemnification Agreement (“Agreement”) is effective as of , 2010, by and between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Ampio”), and (Name) (“Indemnitee”).

SUBSCRIPTION ESCROW AGREEMENT
Subscription Escrow Agreement • December 21st, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This SUBSCRIPTION ESCROW AGREEMENT, dated as of December 20, 2011 (together with Schedule A and Schedule B hereto, this “Agreement”), is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation, with principal offices located at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111 (the “Company”); AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, a New York limited liability trust company, with principal offices located at 6201 15th Avenue, Brooklyn, New York, 11219 (“Escrow Agent”); and Fordham Financial Management, Inc., a Colorado corporation, with principal offices located at 14 Wall Street, New York, New York 10005, as representative for the placement agents named in the Placement Agent Agreement (the “Placement Agent”).

AGREEMENT AND PLAN OF MERGER BY AND AMONG AMPIO PHARMACEUTICALS, INC., AMPIO ACQUISITION, INC., AND THE DMI BIOSCIENCES CONTROL SHAREHOLDERS DATED AS OF SEPTEMBER 4, 2010
Agreement and Plan of Merger • January 7th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of September 4, 2010, by and among DMI BioSciences, Inc., a Colorado corporation (the “Company”), Ampio Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Ampio Acquisition, Inc., a Colorado corporation and wholly-owned subsidiary of Parent (the “Merger Subsidiary”); and the Company’s Control Shareholders (as defined below). Each of the Company, Parent and Merger Subsidiary may be referred to herein as a “Party,” and collectively as the “Parties.”

RESTRICTED STOCK AGREEMENT
Restricted Stock Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate • Colorado

THIS RESTRICTED STOCK AGREEMENT (this “Agreement”) is made effective as of April 17, 2009 (the “Grant Date”), by and between DMI Life Sciences, Inc., a Delaware corporation (the “Company”), and Bruce G. Miller (the “Holder”):

EMPLOYMENT AGREEMENT
Employment Agreement • December 18th, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

This Employment Agreement (“Agreement”) is executed on December 14, 2019 and effective as of January 10, 2020 (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, Colorado 80112 (the “Company”), and Michael Macaluso, an individual (“Executive”) (the Company and Executive each a “Party” and, collectively, the “Parties”).

ASSET PURCHASE AGREEMENT
Asset Purchase Agreement • February 9th, 2012 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This Asset Purchase Agreement (“Agreement”) is entered into by and between Ampio Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111, USA (“Ampio”), and Valeant International (Barbados) SRL (formerly Biovail Laboratories International SRL), a society with restricted liability established under the laws of Barbados, with its principal place of business at Welches, Christ Church, Barbados, West Indies (“VIB”), as of December 2, 2011 (the “Effective Date”).

EMPLOYMENT AGREEMENT
Employment Agreement • March 29th, 2022 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

This Employment Agreement (the "Agreement") is effective as of October 11, 2021 (the “Effective Date”), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA (hereinafter referred to as the "Company"), and Daniel Stokely (“Employee").

WARRANT EXERCISE AGREEMENT
Warrant Exercise Agreement • December 12th, 2018 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations

This Warrant Exercise Agreement (this “Agreement”), dated as of December 11, 2018, is by and between Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Holder”) of a Common Stock Purchase Warrant to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), issued by the Company, which warrant is exercisable at an exercise price (the “Exercise Price”) of $.40 per share (the “Original Warrant”).

VOTING AGREEMENT
Voting Agreement • April 22nd, 2015 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS VOTING AGREEMENT (this “Agreement”), dated as of April 21, 2015, is made between Rosewind Corporation, a Colorado corporation (the “Company”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Shareholder”).

LEASE AGREEMENT by and between AMPIO PHARMACEUTICALS, INC. (“Tenant”) and NCWP - INVERNESS BUSINESS PARK, LLC (“Landlord”) December 13, 2013 373 INVERNESS PARKWAY
Lease Agreement • December 19th, 2013 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations

THIS LEASE AGREEMENT (this “Lease” or this “Agreement”) is made and entered into as of the Effective Date identified in the summary of Basic Lease Terms preceding this Lease by and between the Tenant and Landlord also identified in such summary.

AutoNDA by SimpleDocs
ESCROW AGREEMENT
Escrow Agreement • January 7th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

This Escrow Agreement dated the 30th day of September, 2010 (the “Escrow Agreement”), is entered into by and among Ampio Pharmaceuticals, Inc., a Delaware corporation (“Ampio”); James Kimmel, in his capacity as representative (the “Representative”) for the shareholders (the “Company Shareholders”) of DMI BioSciences, Inc., a Colorado corporation (the “Surviving Corporation;”Ampio, the Surviving Corporation, and the Representative are referred to in this Escrow Agreement collectively as the “Parties,” and individually, a “Party”); and Corporate Stock Transfer, Inc., a national banking association, as escrow agent (the “Escrow Agent”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • September 26th, 2013 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of September 25, 2013, is by and among Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors identified on Schedule I attached hereto (collectively the “Investors”).

EXCLUSIVE LICENSE AGREEMENT
Exclusive License Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate

This Exclusive License Agreement (“Agreement”) effective as of February 17, 2009 (the “Effective Date”) is by and between DMI BioSciences, Inc., a Colorado corporation having its principal place of business at 8400 East Crescent Parkway, Suite 600, Greenwood Village, Colorado 80111 (“DMI”), and Institute For Molecular Medicine, Inc., a non-profit corporation organized and existing under the laws of Colorado, having a place of business at 3531 South Logan Street, Suite D318, Englewood, Colorado 80110 (“IMM”).

EMPLOYMENT AGREEMENT
Employment Agreement • March 17th, 2010 • Chay Enterprises, Inc. • Real estate • Colorado

This Employment Agreement (the “Agreement”), is effective as of April 17, 2009 (the “Effective Date”), between DMI LIFE SCIENCES, INC., a Delaware corporation (with its successors and assigns, referred to as the “Company”), and DAVID BAR-OR, M.D. (“Employee”).

EMPLOYMENT AGREEMENT
Employment Agreement • March 29th, 2022 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

This Employment Agreement (the "Agreement") is effective as of October 11, 2021 (the “Effective Date”), between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 200, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Holli Cherevka, (“Employee").

AMENDMENT TO EMPLOYMENT AGREEMENT
Employment Agreement • February 15th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations

This Amendment to Employment Agreement (the “Amendment”), is effective as of October 1, 2010 (the “Effective Date”) between Ampio Pharmaceuticals, Inc., a Delaware corporation headquartered at 5445 DTC Parkway, PH 4, Greenwood Village, CO 80111, (hereinafter referred to as the “Company”), and Vaughan Clift, M.D. (“Employee”).

AMENDMENT TO AGREEMENT AND PLAN OF MERGER
Agreement and Plan of Merger • March 25th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Colorado

This Amendment, dated as of March 22, 2011 (this “Amendment”), to the Agreement and Plan of Merger, dated as of September 3, 2010 (the “Merger Agreement”), by and among DMI BioSciences, Inc., a Colorado corporation (the “Company”), Ampio Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Ampio Acquisition, Inc., a Colorado corporation and wholly-owned subsidiary of Parent (the “Merger Subsidiary”); and the Company’s Control Shareholders.

AMPIO PHARMACEUTICALS, INC. STOCK OPTION CANCELLATION AND GRANT AGREEMENT FOR EXECUTIVE
Stock Option Cancellation and Grant Agreement for Executive • August 23rd, 2019 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS STOCK OPTION CANCELLATION AND GRANT AGREEMENT FOR EXECUTIVE (“Agreement”) is made and entered into as of the 20th day of August, 2019 (“Grant Date”) by and between Ampio Pharmaceuticals, Inc. (the “Company” or “we”) and Daniel Stokely (the “Grantee”);

STANDARD FORM OFFICE LEASE BETWEEN CSHV DENVER TECH CENTER, LLC, a Delaware limited liability company, as Landlord, AND AMPIO PHARMACEUTICALS, INC., a Delaware corporation, as Tenant Dated: May 20, 2011 For Premises Located At The Quadrant 5445 DTC...
Office Lease • May 23rd, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations

This Standard Form Office Lease (this “Lease”) is made as of May 20, 2011 (the “Lease Date”), by and between CSHV DENVER TECH CENTER, LLC, a Delaware limited liability company (“Landlord”), and AMPIO PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

LOCKUP AGREEMENT
Lockup Agreement • April 24th, 2015 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

THIS LOCKUP AGREEMENT (this “Agreement”) is made and entered into as of April 16, 2015, by and among Rosewind Corporation, a Colorado corporation (together with any successors and assigns thereto, “Parent”), and Ampio Pharmaceuticals, Inc., a Delaware corporation (together with any successors and assigns thereto, “Seller”). Each capitalized term used, but not otherwise defined, herein has the respective meaning ascribed to such term in the Agreement and Plan of Merger, dated as of April 16, 2015, by and among certain subsidiaries of Seller, Parent, and the other parties thereto (the “Merger Agreement”).

AMPIO PHARMACEUTICALS, INC. NOTE EXTENSION AND SUBORDINATION AGREEMENT
Note Extension and Subordination Agreement • February 15th, 2011 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations

On June 23, 2010, the undersigned Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), issued one promissory note (the “Note”) in the amount of $200,000.00 each, and promised to pay to the order of DMI BioSciences, Inc., and its successors or assigns (collectively, the “Holder”), the aggregate sum of $200,000 due under the Note, together with interest at the rate of 6.0% (six percent) per annum until the Note is paid in full. The Note was originally due on September 2, 2010.

AMPIO PHARMACEUTICALS, INC. EXTENTION AGREEMENT FOR NOTES PAYABLE TOTAL PRINCIPAL AMOUNT: $100,000
Ampio Pharmaceuticals, Inc. • February 15th, 2011 • Pharmaceutical preparations

On August 10, 2010, the undersigned Ampio Pharmaceuticals, Inc., a Delaware corporation (the “Maker”), issued one promissory note (the “Note”) in the amount of $100,000.00, and promised to pay to the order of James Ludvik, and his successors or assigns (collectively, the “Holder”), the aggregate sum of $100,000.00 due under the Note, together with interest at the rate of 8.0% (eight percent) per annum until the Note is paid in full. The Note was originally due on January 31, 2011.

AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT
Employment Agreement • July 14th, 2020 • Ampio Pharmaceuticals, Inc. • Pharmaceutical preparations

This Amendment No. 3 to Employment Agreement (“Amendment No. 3”) is executed and entered into on July 13, 2020, (the “Effective Date”), by and among Ampio Pharmaceuticals, Inc. (the “Company”), and Daniel Stokely (“Executive”) (collectively, the “Parties”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!